Leuprolide vs Triptorelin
Both are long-acting GnRH agonists that initially stimulate, then suppress, the reproductive axis by desensitising pituitary receptors. Triptorelin has a D-tryptophan substitution; leuprolide is a nonapeptide ethylamide.
Leuprolide
A GnRH-agonist peptide that first stimulates, then shuts down, the reproductive axis — "medical castration" used in prostate cancer and other hormone-driven conditions.
BEST STUDIED FOR
Reproductive axis
Read the cited profile →
Triptorelin
A GnRH-agonist decapeptide with a D-tryptophan at position 6, used to suppress sex hormones and in assisted reproduction.
BEST STUDIED FOR
Reproductive axis
Read the cited profile →
SIDE BY SIDE
| Leuprolide | Triptorelin | |
|---|---|---|
| The key difference | GnRH agonist (9 amino acids) | GnRH agonist (10 amino acids) |
| Class | Reproductive axis | Reproductive axis |
| Mechanism | Continuous exposure to a potent GnRH agonist desensitises pituitary GnRH receptors: after an initial LH/testosterone flare, gonadal steroid production is suppressed. | The D-amino-acid substitution at position 6 resists breakdown and raises receptor affinity. |
| Status | Registered medicine (prostate cancer, endometriosis, central precocious puberty; also approved in Japan for spinal and bulbar muscular atrophy). | Registered medicine (prostate cancer, endometriosis, adjuvant breast cancer, central precocious puberty, fertility). |
| Reported safety signals | Effects follow from sex-steroid suppression (hot flushes, bone loss); the initial flare is a recognised issue. | As with other GnRH agonists, effects follow from sex-steroid suppression after an initial flare. |
| A key study | Reviews leuprorelin as a GnRH analogue used across sex-hormone-related disorders. (Drugs 1994, PMID 7533699) | Explains how a D-amino acid at position 6 increases enzymatic resistance and receptor affinity. (Ann Urol (Paris) 2005, PMID 16302716) |
WHEN TO RESEARCH WHICH
They are near-equivalent tools for reproductive suppression research; differences lie in formulation and potency. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Leuprolide] Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders — Drugs 1994. PMID 7533699
- [Leuprolide] Clinical pharmacokinetics of depot leuprorelin — Clin Pharmacokinet 2002. PMID 12083977
- [Leuprolide] The Effect of Leuprolide Acetate 11.25 mg 3-Month Formulation in Children with Central Precocious Puberty: A Systematic Review and Meta-analysis — Adv Ther 2025. PMID 40498278
- [Triptorelin] [Pharmacokinetics and pharmacodynamics of triptorelin] — Ann Urol (Paris) 2005. PMID 16302716
- [Triptorelin] Triptorelin embonate (6-month formulation) — Drugs 2010. PMID 20166771
- [Triptorelin] Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer — Drugs 2017. PMID 29177573
FREQUENTLY ASKED
What is the difference between Leuprolide and Triptorelin?
Both are long-acting GnRH agonists that initially stimulate, then suppress, the reproductive axis by desensitising pituitary receptors. Triptorelin has a D-tryptophan substitution; leuprolide is a nonapeptide ethylamide.
What is the regulatory status of Leuprolide and Triptorelin?
Leuprolide: Registered medicine (prostate cancer, endometriosis, central precocious puberty; also approved in Japan for spinal and bulbar muscular atrophy). Triptorelin: Registered medicine (prostate cancer, endometriosis, adjuvant breast cancer, central precocious puberty, fertility).
What safety signals have been reported?
Leuprolide: Effects follow from sex-steroid suppression (hot flushes, bone loss); the initial flare is a recognised issue. Triptorelin: As with other GnRH agonists, effects follow from sex-steroid suppression after an initial flare.
Which studies is this comparison based on?
For Leuprolide: “Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders” (PMID 7533699); “Clinical pharmacokinetics of depot leuprorelin” (PMID 12083977); “The Effect of Leuprolide Acetate 11.25 mg 3-Month Formulation in Children with Central Precocious Puberty: A Systematic Review and Meta-analysis” (PMID 40498278). For Triptorelin: “[Pharmacokinetics and pharmacodynamics of triptorelin]” (PMID 16302716); “Triptorelin embonate (6-month formulation)” (PMID 20166771); “Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer” (PMID 29177573).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use